MiNK Therapeutics, Inc. (INKT) Stock: Dividends & Earnings

Company Overview:

Market Cap: $0

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $8.48 - $16.93

5 Year INKT Performance Metrics:

Total Return (with DRIP): -89.5% (-36.34% CAGR)

Total Return (no DRIP): -89.5% (-36.34% CAGR)

Share Price: -89.5% (-36.34% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $1,046

Total Return $ (with DRIP): -$8,954

INKT Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

INKT Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Projected Future Returns & Dividends for INKT

Based on past 5-year performance, here are INKT growth metrics:

Share price CAGR of -36.34%
Dividend CAGR of +0%

Using INKT CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	INKT (DRIP)	INKT - No DRIP
Current Price	$12.55	$12.55
Start Shares	796.81	796.81
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	796.81	796.81
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$0.14	$12.55
Total Dividends	$0	$0
Final Value	$109	$10,000

Estimated Future Value + Dividends - INKT

NOTE: Above numbers are our estimate based on INKT's Dividend and Price CAGR over past 5 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Company Info

MiNK Therapeutics, Inc. (INKT) had its IPO on , and is traded on NASDAQ stock exchange.

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The company’s platform is designed to support scalable manufacturing of engineered and native iNKT cell programs, with a pipeline that includes therapies for solid tumors and inflammatory conditions. MiNK Therapeutics works at the intersection of cell therapy and immunology, using iNKT cells that are intended to combine tumor-targeting activity with immune-regulating properties. Its current work centers on advancing product candidates through clinical development and building a manufacturing approach suited to reproducible, off-the-shelf delivery. Headquartered in New York, MiNK Therapeutics plays a specialized role in the biotechnology market by developing precision immunotherapies for serious diseases with limited treatment options.

INKT website: https://minktherapeutics.com